Pharmacosmos develops and markets medicines for the treatment of
iron deficiency - and is the developer of CosmoFer.
An independent pharmaceutical company with an ongoing R&D
programme, our goal is to improve treatment options for healthcare
professionals and patients - and we work with exclusive partners in
more than 50 countries worldwide.
More than 70 million doses of CosmoFer (low Mw iron dextran) has
already been administered worldwide since its launch in 2001.
Recently, we obtained marketing authorisation for
Monofer (iron isomaltoside 1000), a treatment for iron
deficiency anaemia that offers patients with various iron needs the
convenience of iron repletion in one visit.
We are a privately-owned company and operate in more than 50
countries worldwide. Our manufacturing is approved by the Danish
Medicines Agency and the US Food & Drug Administration.
Read more about Pharmacosmos at Pharmacosmos.com.